Company / FCF Margin
NovaBay Pharmaceuticals, Inc. FCF Margin History
FY2015-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-35.7%
FY2017
5-year range
-
FY2015-FY2017
Trend
+64.0%
vs FY2016
Sector context
#79 of 131
Health Care
What the data says
At -35.7%, NovaBay Pharmaceuticals, Inc.'s fcf margin ranks #79 of 131 in the Health Care sector. Improved from -426.4% to -35.7% over the past 2 years.
Based on SEC 10-K filings.
-35.7% in FY2017.
Improved from -426.4% to -35.7% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#79 of 131 in Health CareTop 60% of 131This company -35.7% Sector average -646.9%
▼
+94.5% above sector average
Key checks
Key Insights
- In FY2017, fcf margin increased 64.0% year-over-year.
- Currently 611.2pp above the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | -35.7% | +64.0% |
| FY2016 | -99.4% | +76.7% |
| FY2015 | -426.4% | +89.6% |
As of FY2017 · SEC 10-K · Updated Feb 28, 2026